Ventri Labs AB, a new subsidiary of Biotech Fluidics, has unveiled an innovative pump technology that could revolutionise the handling of sensitive biological materials in medical and research applications.

The patented gravity liquid pump technology developed by VentriLabs addresses a long-standing challenge in bioprocessing, clinical applications, and tissue engineering. Conventional mechanical pumps are known to cause significant damage to delicate biological materials, limiting their utility in these critical fields.

According to the company, their gravity-based pump technology has been meticulously engineered to ensure gentle handling of sensitive media. In comparative studies with commonly used peristaltic pumps, VentriLabs’ technology demonstrated a remarkable reduction in destructive mechanical and shearing effects on blood by up to 95%.

Beyond its gentler approach, the new technology offers improved controllability by eliminating the pulsation effects inherent in peristaltic and membrane pumps. This feature is particularly beneficial in filtration applications, where it can lead to enhanced efficiency and yields, potentially resulting in more cost-effective processes for end-users.

Applications across multiple sectors
The technology’s versatility positions it for use across a broad spectrum of applications, from general laboratory work and bioprocessing to clinical systems involving extracorporeal blood circulation.

Dr Robin Öz, CEO of VentriLabs, expressed optimism about the technology’s potential, saying: “Having committed multi-year funding from our parent company and a strong intellectual property portfolio – we are inviting collaborative partners and investors to accelerate the process, and further development of our groundbreaking liquid pump technology in lab, process and clinical applications.”

For more information about gravity liquid pump technology, visit: www.ventrilabs.com